ClinicalTrials.gg
CompletedNCT03942718SLEEPUpdated Nov 10, 2022

Systemic Lupus Erythematosus Exercise Program

An interventional study of Exercise in Systemic Lupus Erythematosus, sponsored by University Medical Center Mainz. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-11-10.

Sponsored by University Medical Center Mainz · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Mar 2018, registered Jan 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 125 studies in Lupus Erythematosus, Systemic with a site in Germany — 26 open to participants now, 47 under way, 19 of them phase 3. Lupus Erythematosus, Systemic · Germany.

Enrollment
95th of 112
30 · median 224
Started
2018
with 7 others
No phase
3 of 125
1 open now
Registered
56th of 125
by date

Among the 125 studies in Lupus Erythematosus, Systemic with a site in Germany, this one is the 95th largest by enrollment of the 112 interventional ones that give a count, is one of 8 that started in 2018, is one of 3 with no phase, and was the 56th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

26 of the 125 studies in Lupus Erythematosus, Systemic with a site in Germany are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Lupus Erythematosus, Systemic with a site in Germany, or all of them as a file.
02

Study summary

This pilot study is a randomized controlled trial to assess the effect of an individualized supervised exercise program in patients with systemic lupus erythematosus (SLE) compared to treatment-as-usual (TAU).

Read the detailed description

The aim of this study is to evaluate the effect of a 12-week individualized exercise program in subjects with SLE in comparison to treatment-as-usual therapy. Several previous studies showed that exercise leads to various benefits in treating SLE, including enhanced aerobic capacity, reduced symptoms of depression and fatigue. Moreover, it has been shown that exercise is well tolerated and does not impair disease activity in SLE negatively. Here, the effects of an individual internet-based exercise therapy for 12 weeks will be evaluated.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Exercise
  • Aerobic training
  • Anaerobic training
  • Internet-based exercise program
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Positive ANA-titer (≥ 1:80) or Anti-dsDNA (≥ 200 IU/ml) or Highly avid-dsDNA autoantibody (≥ 30 IU/ml)
  • Stable therapy more than 30 days before beginning of the study with (0-20 mg/day) or other immunosuppressive medication like Hydroxchloroquin, Chloroquin, Azathioprin, Methotrexat, Mycophenolatmofetil, Cyclosporin, Belimumab, Rituximab

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, Active lupus nephritits, Physical activity more than two times a week
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • No intervention
    Control group

    Participants will obtain no exercise program. After 12 weeks, the patients in the control group will be invited to participate in the training group.

  • Experimental
    Aerobic exercise group

    Participants will obtain aerobic exercise only.

    Other: Exercise

  • Experimental
    Anaerobic exercise group

    Participants will obtain aerobic and anaerobic exercise respectively

    Other: Exercise

Interventions

  • OtherExercise

    Participants will obtain an individualized exercise program based on entrance examination on treadmill.

06

What researchers measure

Primary outcomes

  1. Peak oxygen uptake (VO2peak)

    Change of VO2peak after 12-weeks compared to baseline.

    Time frame: 12-weeks

Secondary outcomes

  1. Fatigue Scale for Motor and Cognitive Functions (FSMC)

    Change of FSMC score after 12-weeks compared to baseline. The FSMC consists of 20 items (five-point Likert scale, from "absolutely agree" to "absolutely disagree") to assess cognitive fatigue (10 items) and motor fatigue (10 items). The summed scores for cognitive and motor fatigue result in the sum score. A cut-off value of 43 indicates mild fatigue, whereas higher values are associated with moderate fatigue (≥53) or severe fatigue (≥63).

    Time frame: 12-weeks

  2. Beck Depression Inventar (BDI)

    Change of BDI score after 12-weeks compared to baseline to measure the severity of depression. The BDI questionnaire consists of 21 sets of statements. Each set consists of 4 statements which are ranked in terms of severity from 0 to 3. The sum of the item scores (range 0-63) indicates the severity of depression. The standardized scale is: 0-8: no depression. 9-13: minimal depression. 14-19: mild depression. 20-28: moderate depression. 29-63: severe depression.

    Time frame: 12-weeks

  3. Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI)

    The Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) - Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) (SELENA-SLEDAI) will be used to measure the disease activity. The index consist of 24 items including clinical and laboratory variables to measure disease activity within the previous 10 days. The maximum score is 105. SLEDAI scores \>3 indicate a mild or moderate flare, SLEDAI ≥12 indicate a severe flare.

    Time frame: 12-weeks

  4. Disease Activity Score 28 (DAS 28)

    Change of DAS 28 score after 12-weeks compared to baseline. The DAS 28 score indicates rheumatoid arthritis disease activity and treatment response. The score composes of 4 measures including the number of swollen/tender joints, C reactive protein and patients health assessment. A total score is calculated using the DAS 28 formula. Values range from 2.0 to 10, whereas higher values indicate higher disease activity.

    Time frame: 12-weeks

  5. Work Ability Index (WAI)

    The WAI self-assessment questionnaire will be used to assess the workability of the patients. The questionnaire covers six dimensions including current workability, as well as past 2 year estimation among others. The answers have different scores, which are summed to a total score, leading to four categories. 7-27 points indicate bad, 28-36 points moderate, 37-43 good, and 44-49 points very good workability.

    Time frame: 12-weeks

  6. Circulating, cell-free Deoxyribonucleic acid (CfDNA)

    The concentration of cfDNA (ng/ml) will be measured during and after acute exercise at baseline and after 12-weeks exercise intervention using quantitative PCR. Compared to healthy subjects SLE patients show higher cfDNA plasma levels.

    Time frame: 12-weeks

  7. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI)

    Change of score on RCLASI after 12-weeks compared to baseline. The RCLASI scoring system includes the RCLASI Activity Score to measure the activity of skin lesions, and the RCLASE Damage Score to measure the damage of skin lesions in patients with discoid lupus erythematosus and cutaneous lupus erythematosus. The score is used as a follow-up parameter for the Lupus activity of the skin. It was also shown that RCLASI correlates well with the physicians and patients global assessment of disease activity.

    Time frame: 12-weeks

  8. Extra cellular vesicles (EVs)

    The relative amount of EV subpopulations will be analyzed before and after acute exercise, as well as after 12-weeks of exercise intervention using bead isolation and or size exclusion chromatography followed by protein marker characterization.

    Time frame: 12-weeks

  9. Autoantibodies

    Change of antinuclear antibodies (ANA) titer after 12-weeks of exercise intervention compared to baseline (standard value ≤1:80).

    Time frame: 12-weeks

  10. Ventilatory threshold (VT)

    Change of VT after 12-weeks compared to baseline.

    Time frame: 12-weeks

  11. Muscle mass

    Change of muscle mass after 12-weeks compared to baseline. Muscle mass will be measured in absolute mass \[kg\] including internal organs using bioelectrical impedance analysis (InBody 3.0 Body composition analyzer).

    Time frame: 12-weeks

  12. Chair-Stand-Test (CST)

    Change of CST after 12-weeks compared to baseline.

    Time frame: 12-weeks

07

Study locations

1 site
  • UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz I. Medizinische Klinik und Poliklinik
    Mainz, Rheinland-Pfalz 55130, Germany
08

References and documents

Publications

  • Boedecker SC, Philippi KFA, Neuberger E, Schmidt S, Pfirrmann D, Haller N, Schwarting A, Simon P, Weinmann-Menke J. Twelve-Week Internet-Based Individualized Exercise Program in Adults With Systemic Lupus Erythematosus: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2020 Nov 3;9(11):e18291. doi: 10.2196/18291. PubMed 33141101 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Apr 2020, 25 months.

Of 123 non-industry interventional studies with no phase under Lupus Erythematosus, Systemic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's 25 months is close to that.

Counting every sponsor, half of 130 studies reached it within 23 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2019
First posted
May 8, 2019
StartActual
Mar 21, 2018
Primary completionActual
Apr 25, 2020
CompletionActual
Aug 1, 2020
Last update
Nov 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03942718
Lead sponsor
University Medical Center Mainz
Responsible party
Prof. Dr. Julia Weinmann-Menke (Head of the Department of Nephrology and Dialysis, University Medical Center Mainz) — Principal investigator
First posted
May 8, 2019
Start date
Mar 21, 2018
Primary completion
Apr 25, 2020
Completion
Aug 1, 2020
Last update
Nov 10, 2022

Study contacts

Julia Weinmann-Menke, Prof. Dr. med
study director · University mainz, Center of medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion